Furthermore, deferoxamine has been found to reduce the release of inflammatory mediators including IL-6 and TNF-α, thereby mitigating tissue damage caused by systemic inflammatory response syndrome (SIRS) [69]. The gene discussed is TNF; the disease is systemic inflammatory response syndrome.